Healthcare - Biotechnology - NASDAQ - US
$ 9.0145
-1.48 %
$ 29.3 M
Market Cap
-0.53
P/E
CASH FLOW STATEMENT
-40.4 M
OPERATING CASH FLOW
51.7 M
INVESTING CASH FLOW
276 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Surrozen, Inc.
| Net Income | -43 M |
| Depreciation & Amortization | 1.91 M |
| Capital Expenditures | -398 K |
| Stock-Based Compensation | 4.37 M |
| Change in Working Capital | -3.93 M |
| Others | -3.47 M |
| Free Cash Flow | -40.8 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (43.0) | (36.0) | (54.6) | (32.7) | (24.4) |
| Depreciation & Amortization | 1.9 | 2.0 | 2.1 | 1.9 | 2.3 |
| Deferred Income Tax | 0 | 0 | 0.4 | 1 K | 0 |
| Stock Based Compensation | 4.4 | 4.5 | 2.3 | 0.6 | 0.8 |
| Other Operating Activities | 0.3 | (6.2) | 1.2 | 1.0 | 1.3 |
| Change in Working Capital | (3.9) | (8.4) | (0.2) | 52 K | (1.1) |
| Cash From Operations | (40.4) | (44.1) | (48.8) | (29.1) | (21.1) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (0.4) | (0.7) | (1.3) | (0.9) | (1.6) |
| Other Items | 52.1 | 39.0 | (76.4) | (14.2) | 0 |
| Cash From Investing Activities | 51.7 | 38.3 | (77.7) | (15.1) | (1.6) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 59 K | (2.6) | 1 K | 1 K | 13 K |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.3 | 42 K | 0.4 | 50.1 | 28.9 |
| Cash From Financing Activities | 0.3 | (2.6) | 124.6 | 50.1 | 28.9 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 11.6 | (8.4) | (1.9) | 5.9 | 29.5 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (40.8) | (44.9) | (50.1) | (30.0) | (22.6) |